Peter Marks‚ Director of the Food and Drug Administration's COVID Influenza Vaccine Program‚ Answers Questions About the New Flu VaccineThe new vaccine from the Food and Drug Administration may have some critics. However‚ Marks has a solid track record in his role as the director of the agency's COVID influenza vaccine program. He and his team make sure the vaccines are safe and effective‚ and they go through a rigorous evidence-based process. Here are some of the questions he'll answer during his appearance:
Federal regulators will likely decide on a brand new proposal. COVID-19 vaccine A top official said that vaccine companies could begin manufacturing for this fall or winter if they design their products in July. Food and Drug Administration's vaccine chief‚ Dr. Peter Marks‚ said that the FDA would make the final decision shortly after the FDA advisory committee met on June 28th to discuss data from vaccine companies regarding the next-generation vaccines being tested. After that‚ the FDA will decide which vaccine companies should use. This decision will be based on the most effective protection‚ even in the presence of new variations this fall or winter. It is similar to the way the flu vaccine was created ahead of the season. We have to decide by July 1st to ensure that manufacturers are aware of what we're looking for so they can start making large quantities. Marks is the director of the FDA department responsible for vaccines and spoke to ABC News during an interview. It is important to consider how to provide the highest level of protection for people with vaccines. This is not only because it would be unrealistic to continue boosting after a few months but because experts expect another spike in colder months. PHOTO: Peter Marks‚ the director of the Center for Biologics Evaluation and Research at the Food and Drug Administration‚ addresses a Senate Health‚ Education‚ Labor and Pensions Committee hearing held in Washington‚ D.C.‚ on March 18‚ 2021. (Susan Walsh/AP/Bloomberg via Getty Images. FILE More: Biden Administration prepares for a challenging winter and fall of COVID-19 Are there any second boosters that can be used for a wider age range? The current rise is already evident. According to the Centers for Disease Control and Prevention‚ cases are increasing and almost a third of country's COVID level is at high or medium risk. Marks stated that the FDA was also discussing internally whether it would open second boosters for a larger age range to help reduce rising incidences. These boosters are currently not available to people older than 50 or for those with immunocompromised. Marks stated that the FDA must make a decision within the next couple of weeks in order to effectively intervene as there are many cases. He said that this discussion has already begun internally. He said that we wouldn't be doing our jobs as public health specialists if it wasn't for thinking about and considering the risks and benefits. Marks stated that hospitalization rates among people younger than 50 after receiving their first booster were still low. This suggests boosters may not be needed for those who are less likely to need them. The FDA is still investigating the risk of mild infections like COVID and whether booster shots could be used to mitigate them. However‚ opening up additional boosters for more people is only a temporary measure. The fall vaccines are designed to provide a longer-lasting‚ more durable protection. Marks stated that we would be looking at a minimum of 10% more in terms of an immune response against this currently-circulating virus. He also outlined the FDA criteria for future vaccines. To make the switch from current vaccines worthwhile‚ the new vaccines must be at least as effective against the subvariants of omicron. PHOTO: On May 5‚ 2022‚ a nurse administered the Pfizer booster shot to a COVID-19 testing and vaccination site in Los Angeles. (Frederic J. Brown/AFP via Getty Images. FILE More: Nearly all states forecast a rise in COVID-19 hospitalizations Who would get a new vaccine? Although it is possible for the advisory committees to change‚ Marks stated that he believes the next generation boosters will be available for all age categories. Marks stated that all age groups should be eligible at the same time. This is in contrast to the long waiting periods between younger and older generations with current vaccines. The FDA hopes that both Pfizer (and Moderna) will produce vaccines targeting the same strains. Marks stated that people are often confused by everything. Having different components for different vaccines can make things more complicated. Booster fatigue a factor According to the CDC only 43% people 65 years and over have received a dose of vaccine in the past six months. This is despite the fact that nearly 9% people were vaccinated in this age group. Public health is concerned that if the booster lasts for less than three to four months it might be recommended that the patient get another. However‚ the majority of patients will not continue coming back and receiving more boosters. Dr. Robert Wachter chairs the University of California San Francisco's department of medicine. Wachter stated that with each loss‚ there are more people. Fall could bring on fatigue by calling for another boost. However‚ if the vaccine proves to be more efficient‚ it could convince others that its worth it again. Although experts are unsure if the fall vaccine will survive for a year‚ they expect that it will still be effective.
This is because the updated vaccine will contain more recent versions of COVID‚ which was developed in 2019. As part of the National Institute of Health study‚ Dr. Paul Goepfert is leading research into the new vaccines. The researchers are looking at vaccines that only target one variant of omicron or vaccines that cover a few variants over the last two years like delta and omicron. Goepfert stated that by the time all of this is over‚ we will know which combination of vaccines gives us the best antibody response to the newer and better variants of the flu shot. Although he believes the vaccine will be more effective in protecting against serious diseases‚ he cautions that it is not possible to stop all infections. Goepfert suggested that we might be able to have an annual vaccine‚ rather than having the booster every three months. However‚ that's only a few more attempts away. More: US experts debate how to update COVID-19 vaccinations Resources in question The overarching question of resource availability remains. These new vaccines and the subsequent ones will be paid for by who? Even though other countries are moving forward with their negotiations with vaccine companies‚ Congress still has not reached a settlement with the White House regarding additional COVID funding. White House COVID Response Coordinator Dr. Ashish Jha said Wednesday that not all Americans who want a vaccine in the fall of 2017 will have one if Congress does not agree to new COVID funding. If the FDA decided that vaccines are not necessary for everyone‚ and that people older than 50 or 65 need another booster shot‚ that would be no problem. Marks expressed optimism that the FDA will allow everyone to get the vaccines if it is the best thing for their health. I don't care about who is paying for what. Marks stated that he is concerned about making sure the recommendations of FDA do the right thing for the country's health. We will therefore make a recommendation based upon all the evidence that is available and what we believe would be the most beneficial for public health over the next year. officials expect to make a decision on the new covid-19-vaccine design by july 1 originally appeared on abcnewsgocom